Ru^III–Morpholine-Derived Thiosemicarbazone-Based Metallodrugs: Lysosome-Targeted Anticancer Agents

ACS Applied Bio Materials, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 13, 2025

The idea of coordinating biologically active ligand systems to metal centers exploit their synergistic effects has gained momentum. Therefore, in this report, three RuIII complexes 1–3 morpholine-derived thiosemicarbazone ligands have been prepared and characterized by spectroscopy HRMS along with the structure 2 through a single-crystal X-ray diffraction study. solution stability was tested using conventional techniques such as UV–vis HRMS. Further, anticancer activity HT-29 HeLa cancer cell lines. To gain insight into mechanism action, cytotoxicity, hydrophobicity, interaction DNA HSA were evaluated different methods absorption, fluorescence, circular dichroism studies. Along favorable biomolecule interaction, revealed potent selectivity toward cells, which is prerequisite for generation an drug. According viability results, 1 highest cytotoxicity among all group, against both respectively. Additionally, fluorescence-active ruthenium selectively target lysosomes, live-cell imaging. disrupt lysosome membrane potential generating excessive amount reactive oxygen species, results apoptotic mode death.

Language: Английский

Unsymmetrical salen-based oxido VIV: Synthesis, characterization, biomolecular interactions, and anticancer activity

Journal of Inorganic Biochemistry, Journal Year: 2024, Volume and Issue: 264, P. 112818 - 112818

Published: Dec. 25, 2024

Language: Английский